JP2011516609A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516609A5 JP2011516609A5 JP2011505123A JP2011505123A JP2011516609A5 JP 2011516609 A5 JP2011516609 A5 JP 2011516609A5 JP 2011505123 A JP2011505123 A JP 2011505123A JP 2011505123 A JP2011505123 A JP 2011505123A JP 2011516609 A5 JP2011516609 A5 JP 2011516609A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- disease
- bronchitis
- agent according
- peritonitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 34
- 206010006451 bronchitis Diseases 0.000 claims 16
- 206010034674 peritonitis Diseases 0.000 claims 13
- 206010035664 Pneumonia Diseases 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 239000004599 antimicrobial Substances 0.000 claims 7
- 206010014561 Emphysema Diseases 0.000 claims 6
- 206010035742 Pneumonitis Diseases 0.000 claims 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 6
- 206010049153 Allergic sinusitis Diseases 0.000 claims 4
- 206010001889 Alveolitis Diseases 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 4
- 206010034650 Peritoneal adhesions Diseases 0.000 claims 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 4
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 4
- 206010003246 arthritis Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 201000009267 bronchiectasis Diseases 0.000 claims 4
- 208000029771 childhood onset asthma Diseases 0.000 claims 4
- 201000001352 cholecystitis Diseases 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 4
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 208000014674 injury Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 4
- 206010039083 rhinitis Diseases 0.000 claims 4
- 201000009273 Endometriosis Diseases 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- 239000003429 antifungal agent Substances 0.000 claims 3
- 229940121375 antifungal agent Drugs 0.000 claims 3
- 239000003443 antiviral agent Substances 0.000 claims 3
- 238000007912 intraperitoneal administration Methods 0.000 claims 3
- 208000000197 Acute Cholecystitis Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 2
- 206010052613 Allergic bronchitis Diseases 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 206010003267 Arthritis reactive Diseases 0.000 claims 2
- 208000036487 Arthropathies Diseases 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 206010056695 Bronchial oedema Diseases 0.000 claims 2
- 206010008614 Cholecystitis acute Diseases 0.000 claims 2
- 206010008617 Cholecystitis chronic Diseases 0.000 claims 2
- 206010009137 Chronic sinusitis Diseases 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010011224 Cough Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 2
- 206010018691 Granuloma Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 208000012659 Joint disease Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 208000011200 Kawasaki disease Diseases 0.000 claims 2
- 208000000913 Kidney Calculi Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 206010029148 Nephrolithiasis Diseases 0.000 claims 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 2
- 201000011152 Pemphigus Diseases 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 206010056626 Pseudopolyp Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims 2
- 206010037765 Radiation pneumonitis Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 206010058556 Serositis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000000491 Tendinopathy Diseases 0.000 claims 2
- 206010043255 Tendonitis Diseases 0.000 claims 2
- 208000026062 Tissue disease Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 210000000621 bronchi Anatomy 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 201000001883 cholelithiasis Diseases 0.000 claims 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 201000009151 chronic rhinitis Diseases 0.000 claims 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000022195 farmer lung disease Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 208000001130 gallstones Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 230000003959 neuroinflammation Effects 0.000 claims 2
- 208000037916 non-allergic rhinitis Diseases 0.000 claims 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 2
- 208000028169 periodontal disease Diseases 0.000 claims 2
- 208000008423 pleurisy Diseases 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 208000005333 pulmonary edema Diseases 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 208000002574 reactive arthritis Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 201000004415 tendinitis Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 206010070419 Chemical peritonitis Diseases 0.000 claims 1
- 206010017835 Gastric ulcer perforation Diseases 0.000 claims 1
- 206010022657 Intestinal infarction Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000004265 Stomach Rupture Diseases 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4460908P | 2008-04-14 | 2008-04-14 | |
| US61/044,609 | 2008-04-14 | ||
| PCT/US2009/040433 WO2009129205A2 (en) | 2008-04-14 | 2009-04-14 | Sparc anti-inflammatory activity and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011516609A JP2011516609A (ja) | 2011-05-26 |
| JP2011516609A5 true JP2011516609A5 (enExample) | 2011-07-07 |
Family
ID=41199678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505123A Pending JP2011516609A (ja) | 2008-04-14 | 2009-04-14 | Ｓｐａｒｃ抗炎症活性及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110152169A1 (enExample) |
| EP (1) | EP2285449A2 (enExample) |
| JP (1) | JP2011516609A (enExample) |
| CN (1) | CN102131547A (enExample) |
| CA (1) | CA2721453A1 (enExample) |
| WO (1) | WO2009129205A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2748022T3 (es) | 2011-11-21 | 2020-03-12 | Univ Tsukuba | Modulador de la actividad, medicamento que comprende el mismo, uso de ratón deficiente del gen de CD300a y anticuerpo antiCD300a |
| US9850309B2 (en) | 2012-11-07 | 2017-12-26 | University Of Tsukuba | Medicament comprising activity modulator for CD300a-expressing cell associated with allergic disease, CD300a gene-deficient mouse, and use of activity modulator for CD300a-expressing cell |
| WO2015033309A2 (en) | 2013-09-05 | 2015-03-12 | Inis Biotech Llc | Sparc (secreted protein, acidic and rich in cysteine), a new target for the treatment and prevention of acute liver failure |
| CN113018281B (zh) * | 2021-02-23 | 2023-02-03 | 中国人民解放军海军军医大学 | 一种Pellino1天然小分子抑制剂及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO1994024267A1 (en) * | 1993-04-20 | 1994-10-27 | Robinson, William, S. | Methods and materials for treatment of individuals infected with intracellular infectious agents |
| US6187307B1 (en) * | 1997-01-31 | 2001-02-13 | Research Corporation Technologies, Inc. | Cancer immunotherapy with semi-allogeneic cells |
| DE19740571C1 (de) * | 1997-09-15 | 1999-03-18 | Gsf Forschungszentrum Umwelt | Verfahren zur Stimulation von T-Zellen mit gewünschter Antigenspezifität |
| US6387664B1 (en) * | 1999-02-26 | 2002-05-14 | Secretary Of Agency Of Industrial Science And Technology | Sparc fusion protein and method for producing the same |
| US9168318B2 (en) * | 2003-12-30 | 2015-10-27 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and methods of using the same |
| WO2006112930A2 (en) * | 2005-02-18 | 2006-10-26 | Abraxis Bioscience, Inc. | Q3 sparc deletion mutant and uses thereof |
-
2009
- 2009-04-14 US US12/937,925 patent/US20110152169A1/en not_active Abandoned
- 2009-04-14 JP JP2011505123A patent/JP2011516609A/ja active Pending
- 2009-04-14 EP EP09732102A patent/EP2285449A2/en not_active Withdrawn
- 2009-04-14 CA CA2721453A patent/CA2721453A1/en not_active Abandoned
- 2009-04-14 WO PCT/US2009/040433 patent/WO2009129205A2/en not_active Ceased
- 2009-04-14 CN CN200980117855XA patent/CN102131547A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020171316A5 (enExample) | ||
| JP2011516609A5 (enExample) | ||
| JP2019058197A5 (enExample) | ||
| GB0804701D0 (en) | Compounds | |
| ES2335498T3 (es) | Nuevo proceso para la preparacion de reflumilast. | |
| RU2010114058A (ru) | Применение пептида в качестве терапевтического средства | |
| JP2011528332A5 (enExample) | ||
| RU2010113990A (ru) | Применение пептида ламинина в качестве терапевтического средства | |
| CN102391289A (zh) | 头孢他啶中间体及头孢他啶的合成方法 | |
| JP2021507690A5 (enExample) | ||
| NZ545963A (en) | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | |
| WO2005021515A3 (en) | Inhibitors of phosphodiesterase type-iv | |
| IL190835A0 (en) | Sulfonamide derivatives, their preparation and use | |
| JP2011505497A5 (enExample) | ||
| JPS58162592A (ja) | セフアロスポリン誘導体およびその製造方法 | |
| CN102476934A (zh) | 一种环保石英石板材 | |
| WO2002008243A1 (en) | Oxidation process for preparing the intermediate 6.alpha.,9.alpha.-difluoro-11.beta.,17.alpha.-dihydroxy-16.alpha.-methyl-androst-1,4-dien-3-one 17.beta.-carboxylic acid | |
| AU2001270906A1 (en) | Oxidation process for preparing the intermediate 6.alpha.,9.alpha.-difluoro-11.beta.,17.alpha.-dihydroxy-16.a lpha.-methyl-androst-1,4-dien-3-one 17.beta.-carboxylic acid | |
| JP2008520712A5 (enExample) | ||
| JP2009541436A5 (enExample) | ||
| WO2006085212A3 (en) | Condensed isoxaline derivatives as inhibitors of phosphodiesterase type-iv | |
| CN101704827A (zh) | 一种新路线的头孢硫脒化合物 | |
| CN103848851A (zh) | 一种盐酸头孢卡品酯的合成方法 | |
| CN106967092B (zh) | 一种头孢西酮的制备方法 | |
| IL180681A0 (en) | Pyridine derivatives, their preparation and use |